The content on this site is intended for healthcare professionals only
Dr Simron Singh speaks to ecancer about the results from the phase 3 Netter-2 trial which evaluates the use of radioligand therapy in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumours.
Dr Singh reports that the hazard ratio for the trial was 0.276 which was a 72% risk reduction for the radioligand therapy compared with the control arm of octreotide.
He details that the median progression-free survival for the radioligand therapy was 22.8 months compared with 8.5 months in the octreotide arm, showing a significant improvement in efficacy.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
ASCO 2024: Lung cancer highlights
EHA 2024: Multiple myeloma roundup
3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma
